| Species |
Human |
| Protein Construction |
| His |
LAP (TGF beta 1) [Leu30-Arg278(C33S)]
Accession # P01137 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LAP (TGF beta 1), His, Human at 5μg/ml (100μl/well) on the plate can bind Biotinylated Human ITGAV&ITGB6, His Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
31.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-48 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Latent TGF beta 1 cDNA encodes a 390 amino acid precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin‑like convertase processes the proprotein to generate an N‑terminal 249 aa latency‑associated peptide (LAP) and a C‑terminal 112 aa mature TGF‑ beta 1. Disulfide‑linked homodimers of LAP and TGF‑ beta 1 remain non‑covalently associated after secretion, forming the small latent TGF‑ beta 1 complex. |
| Synonyms |
CEDLAP; DPD1; TGF beta1; TGFB; TGFB1; TGFbeta; TGF-beta-1; TGF β1; TGFβ; TGF-β-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
